Concept:
Post-ERCP Pancreatitis (PEP) is the most common and feared complication of Endoscopic Retrograde Cholangiopancreatography, requiring an understanding of patient-specific and procedure-specific risk factors.
Explanation:
• Option A: PEP is more common in females, but it is paradoxically more common in younger patients, not older patients. Older age is actually somewhat protective.
• Option B: While therapeutic procedures involving the pancreatic duct (like sphincterotomy) carry risk, diagnostic ERCP—particularly for conditions like suspected Sphincter of Oddi Dysfunction (SOD) where the papilla is repeatedly manipulated or injected—carries an exceptionally high risk of PEP. However, as a blanket statement, complex therapeutic maneuvers generally increase risk overall.
• Option C: Pharmacological prophylaxis with Somatostatin or Octreotide has yielded conflicting results and is not routinely recommended by major guidelines. The proven, guideline-endorsed prophylaxis is the administration of rectal NSAIDs (Indomethacin or Diclofenac) immediately before or after the procedure.
• Option D: The overall incidence of PEP in unselected patients is around 3-5%. However, in defined high-risk cohorts (e.g., young females with Sphincter of Oddi Dysfunction, difficult cannulation, multiple pancreatic duct injections), the incidence rises dramatically and can easily reach 15% (and in some series, up to 30%). Thus, this statement is medically accurate.
Final Answer:
In highly susceptible demographic and procedural cohorts, the incidence of Post-ERCP Pancreatitis can indeed reach up to 15%.